Zealand Pharma A/S (22Z.F)
| Previous close | 44.40 |
| Open | 43.64 |
| Bid | 44.98 x 60000 |
| Ask | 46.34 x 60000 |
| Day's range | 43.64 - 43.64 |
| 52-week range | 25.58 - 44.40 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 2.545B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.91 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 222.65 |
GlobeNewswireZealand Pharma to highlight obesity pipeline at R&D Event on December 5
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts Copenhagen, Denmark, December 4, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines is hosting an Obesity R&D Event in London on Tuesday, December 5th (1:3
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 42 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 4, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securi
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at November 30, 2023
Company announcement – No. 41 / 2023 Total number of shares and voting rights in Zealand Pharma at November 30, 2023 Copenhagen, Denmark, November 30, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a c
